CN101711237B - 氮杂肽衍生物 - Google Patents

氮杂肽衍生物 Download PDF

Info

Publication number
CN101711237B
CN101711237B CN2008800216013A CN200880021601A CN101711237B CN 101711237 B CN101711237 B CN 101711237B CN 2008800216013 A CN2008800216013 A CN 2008800216013A CN 200880021601 A CN200880021601 A CN 200880021601A CN 101711237 B CN101711237 B CN 101711237B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
compounds
atazanavir
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800216013A
Other languages
English (en)
Chinese (zh)
Other versions
CN101711237A (zh
Inventor
史考特·L.·哈柏森
罗格·D.·通
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of CN101711237A publication Critical patent/CN101711237A/zh
Application granted granted Critical
Publication of CN101711237B publication Critical patent/CN101711237B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
CN2008800216013A 2007-06-12 2008-06-12 氮杂肽衍生物 Expired - Fee Related CN101711237B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US60/934,201 2007-06-12
US6762708P 2008-02-29 2008-02-29
US61/067,627 2008-02-29
PCT/US2008/007331 WO2008156632A1 (en) 2007-06-12 2008-06-12 Azapeptide derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011102869075A Division CN102424668A (zh) 2007-06-12 2008-06-12 氮杂肽衍生物

Publications (2)

Publication Number Publication Date
CN101711237A CN101711237A (zh) 2010-05-19
CN101711237B true CN101711237B (zh) 2013-08-07

Family

ID=39730784

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2008800216013A Expired - Fee Related CN101711237B (zh) 2007-06-12 2008-06-12 氮杂肽衍生物
CN2011102869075A Pending CN102424668A (zh) 2007-06-12 2008-06-12 氮杂肽衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011102869075A Pending CN102424668A (zh) 2007-06-12 2008-06-12 氮杂肽衍生物

Country Status (25)

Country Link
US (4) US20090036357A1 (cg-RX-API-DMAC10.html)
EP (3) EP2116532B1 (cg-RX-API-DMAC10.html)
JP (1) JP2010529196A (cg-RX-API-DMAC10.html)
KR (2) KR101185899B1 (cg-RX-API-DMAC10.html)
CN (2) CN101711237B (cg-RX-API-DMAC10.html)
AR (1) AR066972A1 (cg-RX-API-DMAC10.html)
AT (2) ATE447554T1 (cg-RX-API-DMAC10.html)
AU (1) AU2008267048C1 (cg-RX-API-DMAC10.html)
BR (2) BRPI0823520A2 (cg-RX-API-DMAC10.html)
CA (1) CA2692028C (cg-RX-API-DMAC10.html)
CO (1) CO6241121A2 (cg-RX-API-DMAC10.html)
CY (1) CY1109766T1 (cg-RX-API-DMAC10.html)
DE (1) DE602008000255D1 (cg-RX-API-DMAC10.html)
DK (1) DK2003120T3 (cg-RX-API-DMAC10.html)
ES (3) ES2395137T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20100065T1 (cg-RX-API-DMAC10.html)
MX (1) MX2009013565A (cg-RX-API-DMAC10.html)
PL (1) PL2003120T3 (cg-RX-API-DMAC10.html)
PT (1) PT2003120E (cg-RX-API-DMAC10.html)
RS (1) RS51226B (cg-RX-API-DMAC10.html)
RU (2) RU2448958C2 (cg-RX-API-DMAC10.html)
SI (1) SI2003120T1 (cg-RX-API-DMAC10.html)
TW (1) TW200908970A (cg-RX-API-DMAC10.html)
WO (1) WO2008156632A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200909079B (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103899A1 (en) * 2007-02-23 2008-08-28 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
RS51226B (sr) 2007-06-12 2010-12-31 Concert Pharmaceuticals Inc. Derivati azapeptida kao inhibitori hiv proteaze
US9163067B2 (en) * 2008-10-06 2015-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd HIV-1 integrase derived stimulatory peptides interfering with integrase—Rev protein binding
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
AU2010338425B2 (en) 2009-12-21 2015-07-23 Janssen Sciences Ireland Uc Degradable removable implant for the sustained release of an active compound
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
DK3135656T3 (en) 2011-06-20 2019-04-23 H Lundbeck As DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF schizophrenia
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-（2-吡啶基）苄基]-肼羧酸叔丁酯的制备方法
WO2017095761A1 (en) * 2015-12-02 2017-06-08 Merck Sharp & Dohme Corp. Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
SMT202300480T1 (it) 2016-03-28 2024-01-10 Incyte Corp Composti di pirrolotriazina come inibitori di tam
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
TWI821200B (zh) 2017-09-27 2023-11-11 美商英塞特公司 Tam抑制劑之鹽
PT3813800T (pt) 2018-06-29 2025-06-06 Incyte Corp Formulações de um inibidor de axl/mer
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
AU2021257341A1 (en) * 2020-04-16 2022-11-17 The Medical College Of Wisconsin, Inc. Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux
CN115583984A (zh) * 2022-01-11 2023-01-10 嘉兴安谛康生物科技有限公司 氮杂螺类化合物及其制备方法、药物组合物和用途
AU2024283382A1 (en) 2023-05-31 2025-11-13 Gilead Sciences, Inc. Anti-hiv compounds
CN116987024A (zh) * 2023-08-01 2023-11-03 浙江荣耀生物科技股份有限公司 一种阿扎那韦中间体的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014282A2 (en) * 2004-07-06 2006-02-09 Abbott Laboratories Prodrugs of hiv protease inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3689976T2 (de) 1985-05-15 1995-03-16 Wellcome Found Therapeutische Nucleoside und deren Herstellung.
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
DE69331643T2 (de) 1992-12-29 2002-10-31 Abbott Laboratories, Abbott Park Zwischenprodukte zur Herstellung retroviraler proteasehemmenden Verbindungen
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
AU2959397A (en) 1996-05-31 1998-01-05 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
EP1390063B1 (en) 2001-05-03 2004-11-17 F. Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
NZ530722A (en) 2001-08-31 2007-11-30 Bristol Myers Squibb Co Use of atazanavir to reduce plasma LDL and/or triclyceride levels in an HIV-infected patient
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2005027855A2 (en) 2003-02-21 2005-03-31 Jarrow Formulas, Inc. Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
BRPI0518741A2 (pt) 2004-12-03 2008-12-02 Merck & Co Inc uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
JP2010502702A (ja) * 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
RS51226B (sr) 2007-06-12 2010-12-31 Concert Pharmaceuticals Inc. Derivati azapeptida kao inhibitori hiv proteaze
US20090076097A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014282A2 (en) * 2004-07-06 2006-02-09 Abbott Laboratories Prodrugs of hiv protease inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cihlar et al.Suppression of HIV-1 protease inhibitor resistance by posphonate-mediated solvent anchoring.《Journal of molecular biology》.2006,第363卷(第3期),635-647. *
Xu zhongmin et al.Process research and development for an efficient synthesis of the HIV protease inhibitor BMS-232632.《Organic procesws research & development》.2002,第6卷(第3期),323-328. *
Zhang Huiping et al.A facile and efficient syntheis of d3-labelled reyatazTM.《Journal of labelled compounds and radiopharmaceuticals》.2005,第48卷(第14期),1041-1047. *

Also Published As

Publication number Publication date
JP2010529196A (ja) 2010-08-26
DK2003120T3 (da) 2010-03-15
CY1109766T1 (el) 2014-09-10
TW200908970A (en) 2009-03-01
CN101711237A (zh) 2010-05-19
RU2448958C2 (ru) 2012-04-27
HK1136576A1 (en) 2010-07-02
CO6241121A2 (es) 2011-01-20
AU2008267048B2 (en) 2012-05-31
CA2692028C (en) 2013-06-04
PL2003120T3 (pl) 2010-04-30
EP2322509B1 (en) 2012-08-22
US20120165288A1 (en) 2012-06-28
ATE536343T1 (de) 2011-12-15
MX2009013565A (es) 2010-06-02
RU2012101881A (ru) 2013-07-27
EP2322509A1 (en) 2011-05-18
AR066972A1 (es) 2009-09-23
BRPI0813911A2 (pt) 2012-02-22
ZA200909079B (en) 2011-05-25
KR20100020033A (ko) 2010-02-19
US20130041156A1 (en) 2013-02-14
SI2003120T1 (sl) 2010-03-31
ES2394952T3 (es) 2013-02-07
CN102424668A (zh) 2012-04-25
ATE447554T1 (de) 2009-11-15
US8258309B2 (en) 2012-09-04
HRP20100065T1 (hr) 2010-03-31
US8158805B2 (en) 2012-04-17
AU2008267048C1 (en) 2013-01-17
AU2008267048A1 (en) 2008-12-24
US20110009355A1 (en) 2011-01-13
KR20120029480A (ko) 2012-03-26
WO2008156632A1 (en) 2008-12-24
PT2003120E (pt) 2010-02-11
ES2395137T3 (es) 2013-02-08
RU2010100821A (ru) 2011-07-20
EP2116532B1 (en) 2011-12-07
EP2003120B1 (en) 2009-11-04
US20090036357A1 (en) 2009-02-05
ES2356334T3 (es) 2011-04-07
EP2116532A1 (en) 2009-11-11
BRPI0823520A2 (pt) 2013-12-17
RS51226B (sr) 2010-12-31
DE602008000255D1 (de) 2009-12-17
EP2003120B9 (en) 2010-06-02
EP2003120A1 (en) 2008-12-17
CA2692028A1 (en) 2008-12-24
HK1127345A1 (en) 2009-09-25
KR101185899B1 (ko) 2012-09-27

Similar Documents

Publication Publication Date Title
CN101711237B (zh) 氮杂肽衍生物
CN105669751B (zh) 非环核苷酸磷酰胺类化合物及其盐的制备以及在抗病毒方面的应用
US9108902B2 (en) Deuterated 2-amino-3-hydroxypropanoic acid derivatives
WO2009148600A2 (en) Deuterated lysine-based compounds
HK1154862A (en) Azapeptide derivatives as hiv protease inhibitors
HK1136576B (en) Azapeptide derivatives as hiv protease inhibitors
HK1127345B (en) Azapeptide derivatives as hiv protease inhibitors
AU2012216511A1 (en) Azapeptide derivatives
EP2163553A1 (en) Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof
WO2021257669A1 (en) Synthesis of substituted arylmethylureas, analogues, and crystalline forms thereof and methods of using same
KR20210072765A (ko) N-(4-플루오로-3-(6-(3-메틸피리딘-2-일)-[1,2,4]트리아졸로[1,5-a]피리미딘-2-일)페닐)-2,4-디메틸옥사졸-5-카복사미드의 고체 형태

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130807

Termination date: 20150612

EXPY Termination of patent right or utility model